Baviera M, Genovese S, Lepore V, et al. - In this observational cohort study, researchers tested the safety and effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors vs other antihyperglycaemic agents in large and unselected populations of the Lombardy and Apulia regions in Italy. Death and cardiovascular (CV) events were assessed utilizing conditional Cox models in propensity‐score‐matched populations. After propensity‐score matching, the Lombardy cohort involved 18,716 and 11,683 patients and the Apulia cohort 9,772 and 6,046 patients for the GLP‐1RA and SGLT2 inhibitor groups, respectively. The findings from real‐world practice consistently confirm the beneficial effect of GLP‐1RAs and SGLT2 inhibitors on death and CV outcomes in both regions. As a result, these drug classes should be preferentially thought in a broad type 2 diabetes population beyond those with CV disease.